Identification and selection of disease-specific targets is one of the most critical steps in post-genomic drug-discovery. Over-expression of genes and their protein products is often the best starting point for dissecting the pathways that are responsible for the development of specific diseases. Such proteins often serve as molecular targets particularly in cancer, where small molecules are designed to inhibit directly oncogenic proteins that are mutated or overexpressed.

Authors: György Dormán, László Puskás, László Hackler, Liliana Z. Fehér, Cesare Spadoni , Zsolt Lörincz, Tamás Jankovics, László Ürge and Ferenc Darvas

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

(Visited 2 times, 1 visits today)